Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study

The aim of this study was to assess the efficacy and safety of amrubicin for previously treated malignant pleural mesothelioma.

[1]  K. Ramchandran,et al.  Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. , 2019, Lung cancer.

[2]  Y. Obase,et al.  Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer , 2019, Thoracic cancer.

[3]  M. Okada,et al.  Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT) , 2019, Clinical Cancer Research.

[4]  S. Lantuejoul,et al.  Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. , 2019, The Lancet. Oncology.

[5]  N. Pavlakis,et al.  Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  E. Thunnissen,et al.  Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  A. Santoro,et al.  Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. , 2017, The Lancet. Oncology.

[8]  Olivier Molinier,et al.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[9]  T. Yamanaka,et al.  Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial) , 2015, International Journal of Clinical Oncology.

[10]  P. V. Van Schil,et al.  Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  D. Ettinger,et al.  Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Stahel,et al.  Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  T. Powles,et al.  The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. , 2009, Lung cancer.

[14]  R. Ramlau,et al.  Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  F. Ardissone,et al.  Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[16]  Yukiko Nakamura,et al.  Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third-Line Chemotherapy for Small Cell Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  K. Uematsu,et al.  Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Nackaerts,et al.  Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  M. Byrne,et al.  Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  J. Herndon,et al.  Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). , 2001, Lung cancer.

[21]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Scagliotti,et al.  Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Herndon,et al.  Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. , 2001, Lung cancer.

[24]  J. Shamash,et al.  Phase II study of vinorelbine in patients with malignant pleural mesothelioma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Giaccone,et al.  A phase II study of gemcitabine in patients with malignant pleural mesothelioma , 1999 .

[26]  G. Giaccone,et al.  A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. , 1999, Cancer.

[27]  Satoko Mizuno,et al.  A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II‐DNA Complex , 1998, Japanese journal of cancer research : Gann.

[28]  T. Yamaoka,et al.  Cytotoxicity of Amrubicin, a Novel 9‐Aminoanthracycline, and Its Active Metabolite Amrubicinol on Human Tumor Cells , 1998, Japanese journal of cancer research : Gann.

[29]  V. Rusch,et al.  A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. , 1996, Lung cancer.

[30]  J. Peto,et al.  Continuing increase in mesothelioma mortality in Britain , 1995, The Lancet.

[31]  H. Hansen,et al.  Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. , 1985, Cancer treatment reports.

[32]  B. Ponder,et al.  Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single‐agent 5‐fluorouracil and adriamycin , 1984, Cancer.